πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 2,828 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11236044

Selective inhibitors of 12(S)-lipoxygenase (12-LOX) and methods for use of the same

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11236080

Protein kinase inhibitors

Princeton Drug Discovery, Inc Β· Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11234939

Dosage forms comprising a plasma kallikrein inhibitor

KalVista Pharmaceuticals Limited Β· Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11230544

Substituted 1,3,4-thiadiazoles as GLS1 inhibitors

Medshine Discovery Inc. Β· Granted Tue Jan 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11229679

Compositions for treating heart disease by inhibiting the action of mAKAPΞ²

Anchored RSK3 Inhibitors, LLC Β· Granted Tue Jan 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11230530

Human plasma kallikrein inhibitors

BioCryst Pharmaceuticals, Inc. Β· Granted Tue Jan 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11230537

Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[2-oxopyr

KalVista Pharmaceuticals Limited Β· Granted Tue Jan 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11230542

Inhibitors of integrated stress response pathway

PRAXIS BIOTECH LLC Β· Granted Tue Jan 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11225469

Inhibitors of phosphoglycerate dehydrogenase (PHGDH) and uses thereof

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jan 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11225477

Inhibitors of influenza virus replication, application methods and uses thereof

SUNSHINE LAKE PHARMA CO., LTD. Β· Granted Tue Jan 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11225514

Nanobodies against cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory f

The Regents of the University of California Β· Granted Tue Jan 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11220479

Glucosylceramide synthase inhibitors and therapeutic methods using the same

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Jan 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11220509

Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors

Mirati Therapeutics, Inc. Β· Granted Tue Jan 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11220486

Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE Β· Granted Tue Jan 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11220524

Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)

Prelude Therapeutics, Incorporated Β· Granted Tue Jan 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11220501

Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3S,4S)-4-amino-3-methyl-2-o

Revolution Medicines, Inc. Β· Granted Tue Jan 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11213513

Compositions and methods for promoting hair growth with Mpc1 inhibitors

The Regents of the University of California Β· Granted Tue Jan 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11214567

Small molecule inhibitors of MYC and uses thereof

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Jan 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11214574

Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)

Prelude Therapeutics, Incorporated Β· Granted Tue Jan 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11208416

Selective inhibitors of protein arginine methytransterase 5 (PRMT5)

Prelude Therapeutics, Incorporated Β· Granted Tue Dec 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11208432

Inhibitors of glucocorticoid receptor

ORIC PHARMACEUTICALS, INC. Β· Granted Tue Dec 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11207314

Methods of treating cancer patients with farnesyltransferase inhibitors

Kura Oncology, Inc. Β· Granted Tue Dec 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11208405

Pyrrole derivatives as PLK1 inhibitors

SENTINEL ONCOLOGY LIMITED Β· Granted Tue Dec 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11208413

Pyrimidopyrimidinones useful as wee-1 kinase inhibitors

ALMAG DISCOVERY LIMITED Β· Granted Tue Dec 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted